Antibodies that block the interaction between PD-1 and PD-L1 have recently been approved for the treatment of melanoma, lung, metastatic bladder cancer, advanced renal cell, head and neck and Hodgkin's lymphoma [18–24]. Here, CD274 is linked to melanoma.